Due to the protective vascular and hormonal actions of SGLT2 inhibitors, the use of this agent may be safely extended to patients with renal dysfunction and/or hyperkalaemia in the long‐term facilitating the initiation of other HF therapies. This evidence concerns the gene SLC5A2 and hydrops fetalis.